MedTrace Logo

Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer

NCT01075113 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-08-20

No results posted yet for this study

Summary

This phase I trial is studying the side effects and best dose of vorinostat when given together with sorafenib tosylate in treating patients with advanced liver cancer. Sorafenib tosylate and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.

Conditions

Interventions

DRUG

sorafenib tosylate

Given orally

DRUG

vorinostat

Given orally

Sponsors & Collaborators

  • Massey Cancer Center

    collaborator OTHER

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Andrew S. Poklepovic, MD · Massey Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-10
Primary Completion
2017-02-02
Completion
2019-07-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01075113 on ClinicalTrials.gov